- Home
- CADL vs FENC Comparison
CADL vs FENC Comparison
Compare CADL & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CADL | FENC |
|---|---|---|
| Founded | 1999 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 339.8M | 276.3M |
| IPO Year | 2021 | 2001 |
Fundamental Metrics
Financial Performance| Metric | CADL | FENC |
|---|---|---|
| Price | $6.24 | $7.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | ★ $19.43 | $15.00 |
| AVG Volume (30 Days) | ★ 706.6K | 177.2K |
| Earning Date | 03-12-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $38,790,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $70.78 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.25 | $4.68 |
| 52 Week High | $13.68 | $9.92 |
Technical Indicators
Market Signals| Indicator | CADL | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 56.82 | 50.43 |
| Support Level | $5.88 | $7.35 |
| Resistance Level | $6.62 | $7.84 |
| Average True Range (ATR) | 0.38 | 0.32 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 71.43 | 43.42 |
Price Performance
Historical ComparisonAbout CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.